JP2017505620A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017505620A5 JP2017505620A5 JP2016549077A JP2016549077A JP2017505620A5 JP 2017505620 A5 JP2017505620 A5 JP 2017505620A5 JP 2016549077 A JP2016549077 A JP 2016549077A JP 2016549077 A JP2016549077 A JP 2016549077A JP 2017505620 A5 JP2017505620 A5 JP 2017505620A5
- Authority
- JP
- Japan
- Prior art keywords
- recombinant protein
- culture
- transfected
- days
- mammalian host
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 30
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 15
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 15
- 210000004027 cell Anatomy 0.000 claims 13
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 12
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 230000004988 N-glycosylation Effects 0.000 claims 8
- 238000004113 cell culture Methods 0.000 claims 7
- 230000037361 pathway Effects 0.000 claims 6
- 210000004962 mammalian cell Anatomy 0.000 claims 5
- 230000010412 perfusion Effects 0.000 claims 5
- 101150030635 Mgat1 gene Proteins 0.000 claims 4
- 101150093077 Mgat2 gene Proteins 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 3
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims 2
- -1 antibodies Proteins 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229950006780 n-acetylglucosamine Drugs 0.000 claims 2
- 101100491335 Caenorhabditis elegans mat-2 gene Proteins 0.000 claims 1
- 102100040428 Chitobiosyldiphosphodolichol beta-mannosyltransferase Human genes 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 108091006020 Fc-tagged proteins Proteins 0.000 claims 1
- 101000891557 Homo sapiens Chitobiosyldiphosphodolichol beta-mannosyltransferase Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- DINOPBPYOCMGGD-VEDJBHDQSA-N Man(a1-2)Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-6)]Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)O3)O)O2)O)[C@@H](CO)O1 DINOPBPYOCMGGD-VEDJBHDQSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 1
- 108090000992 Transferases Proteins 0.000 claims 1
- 102000004357 Transferases Human genes 0.000 claims 1
- 102100033782 UDP-galactose translocator Human genes 0.000 claims 1
- 108010075920 UDP-galactose translocator Proteins 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 229940072221 immunoglobulins Drugs 0.000 claims 1
- 238000001471 micro-filtration Methods 0.000 claims 1
- 238000010899 nucleation Methods 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 239000004017 serum-free culture medium Substances 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 238000000108 ultra-filtration Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461933137P | 2014-01-29 | 2014-01-29 | |
| US61/933,137 | 2014-01-29 | ||
| PCT/US2014/069744 WO2015116315A1 (en) | 2014-01-29 | 2014-12-11 | Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019011871A Division JP6797950B2 (ja) | 2014-01-29 | 2019-01-28 | 組換えタンパク質のグリコシル化を調節するためのｎ−グリコシル化経路制御因子の過剰発現 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017505620A JP2017505620A (ja) | 2017-02-23 |
| JP2017505620A5 true JP2017505620A5 (OSRAM) | 2017-11-30 |
| JP6474420B2 JP6474420B2 (ja) | 2019-02-27 |
Family
ID=53757626
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549077A Active JP6474420B2 (ja) | 2014-01-29 | 2014-12-11 | 組換えタンパク質のグリコシル化を調節するためのｎ−グリコシル化経路制御因子の過剰発現 |
| JP2019011871A Active JP6797950B2 (ja) | 2014-01-29 | 2019-01-28 | 組換えタンパク質のグリコシル化を調節するためのｎ−グリコシル化経路制御因子の過剰発現 |
| JP2020190707A Active JP7034236B2 (ja) | 2014-01-29 | 2020-11-17 | 組換えタンパク質のグリコシル化を調節するためのｎ－グリコシル化経路制御因子の過剰発現 |
| JP2022029077A Active JP7788307B2 (ja) | 2014-01-29 | 2022-02-28 | 組換えタンパク質のグリコシル化を調節するためのｎ－グリコシル化経路制御因子の過剰発現 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019011871A Active JP6797950B2 (ja) | 2014-01-29 | 2019-01-28 | 組換えタンパク質のグリコシル化を調節するためのｎ−グリコシル化経路制御因子の過剰発現 |
| JP2020190707A Active JP7034236B2 (ja) | 2014-01-29 | 2020-11-17 | 組換えタンパク質のグリコシル化を調節するためのｎ－グリコシル化経路制御因子の過剰発現 |
| JP2022029077A Active JP7788307B2 (ja) | 2014-01-29 | 2022-02-28 | 組換えタンパク質のグリコシル化を調節するためのｎ－グリコシル化経路制御因子の過剰発現 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10227627B2 (OSRAM) |
| EP (1) | EP3099806A1 (OSRAM) |
| JP (4) | JP6474420B2 (OSRAM) |
| KR (3) | KR102519540B1 (OSRAM) |
| CN (2) | CN113774084B (OSRAM) |
| AU (3) | AU2014380174C1 (OSRAM) |
| BR (1) | BR112016017606A2 (OSRAM) |
| CA (1) | CA2938079C (OSRAM) |
| CL (1) | CL2016001900A1 (OSRAM) |
| EA (2) | EA037565B1 (OSRAM) |
| IL (3) | IL282517B (OSRAM) |
| MX (2) | MX377780B (OSRAM) |
| SG (1) | SG10201912081RA (OSRAM) |
| WO (1) | WO2015116315A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101936049B1 (ko) | 2015-10-15 | 2019-01-08 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 생산방법 |
| US12503700B2 (en) * | 2017-03-14 | 2025-12-23 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
| IL321253A (en) | 2018-05-01 | 2025-08-01 | Amgen Inc | Antibodies with a modulated glycan profile |
| CN109576212B (zh) * | 2018-12-14 | 2021-06-22 | 杭州奕安济世生物药业有限公司 | 高密度接种培养中种子细胞的培养方法及其应用 |
| BR112021024923A2 (pt) * | 2019-06-10 | 2022-02-15 | Cho Plus Inc | Métodos de preparação de uma linha celular, de produção de um produto farmacêutico, de obtenção de uma linha celular e de produção de uma proteína, linhas celulares produtora e híbrida, sistema para produção de alto nível de produtos farmacêuticos, e, produto farmacêutico |
| AU2022262421A1 (en) | 2021-04-23 | 2023-10-19 | Amgen Inc. | Anti-tslp antibody compositions and uses thereof |
| MX2023012903A (es) * | 2021-05-03 | 2023-11-08 | Boehringer Ingelheim Int | Metodo para producir spesolimab. |
| CN113684322B (zh) * | 2021-09-09 | 2024-01-23 | 上海药明生物技术有限公司 | 一种降低抗体类蛋白高聚甘露糖型水平的方法 |
| CN114525252B (zh) * | 2022-03-10 | 2023-12-01 | 广州源井生物科技有限公司 | 一种提高mda-mb-231单细胞克隆形成率的单克隆增强培养基与培养方法及其应用 |
| AR130862A1 (es) | 2022-10-26 | 2025-01-29 | Amgen Inc | Composiciones de anticuerpos anti-tslp y usos de las mismas |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| AU588819B2 (en) | 1984-10-29 | 1989-09-28 | Immunex Corporation | Cloning of human granulocyte-macrophage colony stimulating factor gene |
| US5672502A (en) | 1985-06-28 | 1997-09-30 | Celltech Therapeutics Limited | Animal cell culture |
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
| AU643427B2 (en) | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
| US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
| DK0939121T4 (da) | 1989-09-12 | 2008-02-04 | Ahp Mfg B V | TNF-bindende proteiner |
| US6204363B1 (en) | 1989-10-16 | 2001-03-20 | Amgen Inc. | Stem cell factor |
| US5149792A (en) | 1989-12-19 | 1992-09-22 | Amgen Inc. | Platelet-derived growth factor B chain analogs |
| US5272064A (en) | 1989-12-19 | 1993-12-21 | Amgen Inc. | DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof |
| US5350683A (en) | 1990-06-05 | 1994-09-27 | Immunex Corporation | DNA encoding type II interleukin-1 receptors |
| AU651596B2 (en) | 1990-06-05 | 1994-07-28 | Immunex Corporation | Type II interleukin-1 receptors |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| CA2146559A1 (en) | 1992-10-23 | 1994-05-11 | Melanie K. Spriggs | Methods of preparing soluble, oligomeric proteins |
| US5981713A (en) | 1994-10-13 | 1999-11-09 | Applied Research Systems Ars Holding N.V. | Antibodies to intereleukin-1 antagonists |
| EP1666591B1 (en) | 1995-06-29 | 2011-03-23 | Immunex Corporation | Cytokine that induces apoptosis |
| US6613544B1 (en) | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
| US6096728A (en) | 1996-02-09 | 2000-08-01 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| US6271349B1 (en) | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| US6337072B1 (en) | 1998-04-03 | 2002-01-08 | Hyseq, Inc. | Interleukin-1 receptor antagonist and recombinant production thereof |
| AU1920301A (en) | 1999-11-17 | 2001-05-30 | Immunex Corporation | Receptor activator of nf-kappa b |
| US6544424B1 (en) | 1999-12-03 | 2003-04-08 | Refined Technology Company | Fluid filtration system |
| GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
| GB0025144D0 (en) | 2000-10-13 | 2000-11-29 | Medical Res Council | Concatenated nucleic acid sequences |
| US20040202995A1 (en) | 2003-04-09 | 2004-10-14 | Domantis | Nucleic acids, proteins, and screening methods |
| US20050186577A1 (en) * | 2004-02-20 | 2005-08-25 | Yixin Wang | Breast cancer prognostics |
| PL1720972T3 (pl) * | 2004-03-05 | 2014-06-30 | Dpx Holdings Bv | Proces hodowli komórek poprzez ciągłą perfuzję i zmienny przepływ styczny |
| MX2007003320A (es) | 2004-09-24 | 2007-05-18 | Amgen Inc | Moleculas fc modificadas. |
| US8053238B2 (en) | 2005-10-31 | 2011-11-08 | Unhwa Corporation | Isolated population of plant single cells and method of preparing the same |
| US20070190057A1 (en) * | 2006-01-23 | 2007-08-16 | Jian Wu | Methods for modulating mannose content of recombinant proteins |
| US20100145032A1 (en) * | 2007-01-18 | 2010-06-10 | Suomen Punainen Risti, Veripalelu | Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof |
| US20100221823A1 (en) * | 2007-06-11 | 2010-09-02 | Amgen Inc. | Method for culturing mammalian cells to improve recombinant protein production |
| TW201028431A (en) * | 2008-10-31 | 2010-08-01 | Lonza Ag | Novel tools for the production of glycosylated proteins in host cells |
| EP2421892A1 (en) * | 2009-04-20 | 2012-02-29 | Pfizer Inc. | Control of protein glycosylation and compositions and methods relating thereto |
| US20130196410A1 (en) * | 2010-03-05 | 2013-08-01 | Alnylam Pharmaceuticals, Inc | Compositions and methods for modifying the glycosylation pattern of a polypeptide |
| EP2556163B1 (en) * | 2010-04-07 | 2016-08-10 | Momenta Pharmaceuticals, Inc. | Method for quantifying high mannose containing glycoforms |
| TW201209160A (en) * | 2010-04-27 | 2012-03-01 | Lonza Ag | Improved glycosylation of proteins in host cells |
| US9133493B2 (en) | 2011-04-21 | 2015-09-15 | Amgen Inc. | Method for culturing mammalian cells to improve recombinant protein production |
| EP2802654B1 (en) | 2012-01-11 | 2019-04-03 | Sigma Aldrich Co. LLC | Production of recombinant proteins with simple glycoforms |
-
2014
- 2014-12-11 CN CN202110902965.XA patent/CN113774084B/zh active Active
- 2014-12-11 CA CA2938079A patent/CA2938079C/en active Active
- 2014-12-11 EA EA201691532A patent/EA037565B1/ru unknown
- 2014-12-11 EA EA202190244A patent/EA202190244A3/ru unknown
- 2014-12-11 WO PCT/US2014/069744 patent/WO2015116315A1/en not_active Ceased
- 2014-12-11 MX MX2016009911A patent/MX377780B/es active IP Right Grant
- 2014-12-11 CN CN201480074585.XA patent/CN106170554B/zh active Active
- 2014-12-11 KR KR1020227019897A patent/KR102519540B1/ko active Active
- 2014-12-11 KR KR1020167021676A patent/KR102301034B1/ko active Active
- 2014-12-11 EP EP14821424.0A patent/EP3099806A1/en active Pending
- 2014-12-11 SG SG10201912081RA patent/SG10201912081RA/en unknown
- 2014-12-11 AU AU2014380174A patent/AU2014380174C1/en active Active
- 2014-12-11 IL IL282517A patent/IL282517B/en unknown
- 2014-12-11 BR BR112016017606A patent/BR112016017606A2/pt not_active Application Discontinuation
- 2014-12-11 JP JP2016549077A patent/JP6474420B2/ja active Active
- 2014-12-11 KR KR1020217028516A patent/KR102410393B1/ko active Active
-
2016
- 2016-07-24 IL IL246914A patent/IL246914B/en active IP Right Grant
- 2016-07-26 CL CL2016001900A patent/CL2016001900A1/es unknown
- 2016-07-29 MX MX2020012356A patent/MX2020012356A/es unknown
-
2018
- 2018-09-13 US US16/130,879 patent/US10227627B2/en active Active
- 2018-11-15 AU AU2018264100A patent/AU2018264100C1/en active Active
-
2019
- 2019-01-28 JP JP2019011871A patent/JP6797950B2/ja active Active
- 2019-01-29 US US16/261,311 patent/US10655156B2/en active Active
- 2019-11-24 IL IL270861A patent/IL270861B/en active IP Right Grant
-
2020
- 2020-05-15 US US16/875,832 patent/US10907186B2/en active Active
- 2020-09-23 AU AU2020239681A patent/AU2020239681C1/en active Active
- 2020-11-17 JP JP2020190707A patent/JP7034236B2/ja active Active
-
2022
- 2022-02-28 JP JP2022029077A patent/JP7788307B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017505620A5 (OSRAM) | ||
| TWI702226B (zh) | 治療性蛋白質藥物物質之整合連續製造 | |
| TWI670279B (zh) | 抗體純化及純度監測 | |
| Gronemeyer et al. | Trends in upstream and downstream process development for antibody manufacturing | |
| van Reis et al. | Bioprocess membrane technology | |
| Fliedl et al. | Human cell lines for the production of recombinant proteins: on the horizon | |
| TWI720289B (zh) | 用於增加重組蛋白質之甘露糖含量之方法 | |
| WO2009091912A3 (en) | Improved mammalian expression vectors and uses thereof | |
| WO2008091740A4 (en) | Polyelectrolyte precipitation and purification of antibodies | |
| JP2017538446A5 (OSRAM) | ||
| WO2015004679A1 (en) | Improved process for production of monoclonal antibodies | |
| NZ701825A (en) | Heterodimeric antibody fc-containing proteins and methods for production thereof | |
| Zydney | Membrane technology for purification of therapeutic proteins | |
| WO2013093760A3 (en) | Compositions, methods, and kits for preparing sialylated recombinant proteins | |
| BR112012011980A2 (pt) | Métodos de produzir células transformadas de yarrowia lipolytica e proteínas-alvocompreendendo n-glicanos, células transformadas de yarrowia lipolytica e suas culturas, bem como composição compreendendo glicoproteínas | |
| JP2015532096A5 (OSRAM) | ||
| IL276211B1 (en) | Process for producing hu14.18k322a monoclonal antibody | |
| CN107384932B (zh) | 抗人cd20人源化单克隆抗体mil62、其制备方法及用途 | |
| IL307155B1 (en) | Antibodies with modulated glycan profiles | |
| HRP20250491T1 (hr) | Upotreba monensina za regulaciju glikozilacije rekombinantnih proteina | |
| JP2019514411A5 (OSRAM) | ||
| Hart et al. | Human cell line-derived monoclonal IgA antibodies for cancer immunotherapy | |
| US20160222429A1 (en) | Method for the clarification of high density crude cell culture harvest | |
| JP2016535071A5 (OSRAM) | ||
| JP2017536808A (ja) | 細胞を培養する方法 |